Executive chair steps down amid funding uncertainty
Listed biotech company, Tissue Regenix has announced that its executive chair, John Samuel plans to step down from from both that role and as a board member after 12 years with the company.
Thew news follows a rocky 12 months for the Leeds-based business which included a drop in share value following it failing a covenant test for £16m loan, and a cyber security incident in the USA in January.
Samuel is the third senior figure to leave the company since August with the company’s CEO, Steve Couldwell, stepping down in down tha... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
